Spectrum Pharmaceuticals to acquire Allos Therapeutics:
HENDERSON, Nev. & WESTMINSTER, Colo.---Apr 5, 2012 - Spectrum Pharmaceuticals and Allos Therapeutics, Inc. today announced that they have signed a definitive agreement under which Spectrum will acquire all of the outstanding shares of Allos for $1.82 per share in cash plus one Contingent Value Right.
Spectrum Pharmaceuticals, Inc., a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced the date and time for its third quarter 2010 corporate update and pipeline review conference call.